Search - tctmd.com

Displaying 1 - 20 of 114

Sort: Relevancy | Date

POLY-HF: Polypill Pays Dividends in Patients With HFrEF

News Conference News AHA 2025

POLY-HF: Polypill Pays Dividends in Patients With HFrEF

November 14, 2025

Artificial Intelligence Successfully Adjudicates Clinical Events in CV Trials

News Conference News AHA 2025

Artificial Intelligence Successfully Adjudicates Clinical Events in CV Trials

Yael L. Maxwell

November 13, 2025

Beta-blockers Not Helpful After MI in Patients With Preserved EF

News Conference News AHA 2025

Beta-blockers Not Helpful After MI in Patients With Preserved EF

Yael L. Maxwell

November 12, 2025

CELEBRATE: Zalunfiban, a Novel Glycoprotein IIb/IIIa Inhibitor, Helps in STEMI

News Conference News AHA 2025

CELEBRATE: Zalunfiban, a Novel Glycoprotein IIb/IIIa Inhibitor, Helps in STEMI

Michael O'Riordan

November 11, 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

News Conference News AHA 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

Michael O'Riordan

November 08, 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

News Conference News AHA 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

November 08, 2025

What’s Going to Be Hot at AHA 2025?

News Opinion Editor's Corner AHA 2025

What’s Going to Be Hot at AHA 2025?

Michael O'Riordan

November 05, 2025

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

News Conference News AHA 2024

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

Michael O'Riordan

November 18, 2024

OPTION: LAAO Matches Up to DOACs After Ablation, but Questions Remain

News Conference News AHA 2024

OPTION: LAAO Matches Up to DOACs After Ablation, but Questions Remain

November 18, 2024

Lifestyle and Risk Factors Matter for AF Burden—Metformin May Not: TRIM-AF

News Conference News AHA 2024

Lifestyle and Risk Factors Matter for AF Burden—Metformin May Not: TRIM-AF

November 18, 2024

GLORIOUS: Neither Exenatide Nor Restrictive Oxygenation Boost CV Surgery Outcomes

News Conference News AHA 2024

GLORIOUS: Neither Exenatide Nor Restrictive Oxygenation Boost CV Surgery Outcomes

Michael O'Riordan

November 17, 2024

SUMMIT: Tirzepatide ‘Huge Win’ for HFpEF Patients With Obesity

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Michael O'Riordan

November 16, 2024

Intensive BP Lowering in Diabetes Reduces CV Events: BPROAD

News Conference News AHA 2024

Intensive BP Lowering in Diabetes Reduces CV Events: BPROAD

Yael L. Maxwell

November 16, 2024

One Hundred Years and Beyond: What's Going to Be Hot at AHA 2024

News Conference News AHA 2024

One Hundred Years and Beyond: What's Going to Be Hot at AHA 2024

November 14, 2024

Novel AI-Guided CV Risk Prediction Takes Aim at Coronary Inflammation

News Conference News AHA 2023

Novel AI-Guided CV Risk Prediction Takes Aim at Coronary Inflammation

November 17, 2023

ESPRIT: Intensive BP-Lowering Reduces MACE in Chinese Patients

News Conference News AHA 2023

ESPRIT: Intensive BP-Lowering Reduces MACE in Chinese Patients

November 13, 2023

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

News Conference News AHA 2023

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

November 11, 2023

Coincidental Nonischemic Cardiomyopathy Impacts Prognosis in CAD

News Conference News AHA 2023

Coincidental Nonischemic Cardiomyopathy Impacts Prognosis in CAD

November 09, 2023

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

News Conference News AHA 2023

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

November 07, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.